Policy & Regulation
Framework legalised in 2019 but industry slow to implement — no patients have received treatment.
Lithuania legalised the manufacturing, import, export, and distribution of medical cannabis in October 2018, effective May 2019. Companies can obtain licences through the State Medicines Control Agency. However, the industry has been slow to develop and no patients have received medical cannabis treatment.
On 11 October 2018, Lithuania legalised the manufacturing, import, export, and distribution of medical cannabis. The law came into effect on 1 May 2019.
Companies can obtain licences for manufacturing, wholesale, import and export, and retail of medical cannabis products through the State Medicines Control Agency.
The cultivation of medical cannabis in Lithuania is not permitted under the current framework.
Who can prescribe: Theoretically available to patients suffering from cancer, multiple sclerosis, epilepsy, and AIDS.
In practice, the industry has been slow to develop and no patients have received medical cannabis treatment since the law came into effect in 2019.
Reimbursement: No framework established.
No medical cannabis products are currently available to patients in Lithuania.
Despite the legal framework, the market has not developed to the point of providing patient access.
Licences for manufacturing, import, export, and distribution are available through the State Medicines Control Agency, though commercial activity remains minimal.
Cultivation is not permitted, limiting Lithuania's potential as a production hub.